Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;225(1):103-113.
doi: 10.1016/j.jamcollsurg.2017.02.006. Epub 2017 Feb 20.

Liver Transplantation for Malignant Primary Pediatric Hepatic Tumors

Adeel S Khan  1 , Brittany Brecklin, Neeta Vachharajani, Vijay Subramanian, Michelle Nadler, Janice Stoll, Yumirle Turmelle, Jeffery A Lowell, William C Chapman, Majella Mb Doyle
Affiliations

Liver Transplantation for Malignant Primary Pediatric Hepatic Tumors

Adeel S Khan et al. J Am Coll Surg. 2017 Jul.

Abstract

Background: Malignant primary pediatric hepatic tumors (MPPHTs) are rare and account for approximately 1% of all childhood malignancies. In recent years, liver transplantation has emerged as a viable treatment options for select patients with MPPHTs.

Study design: We performed a single-center retrospective study using a prospective database to compare outcomes of pediatric liver transplant recipients, with and without cancer, between January 2000 and December 2014.

Results: One hundred fifty-three children underwent 173 liver transplantations during the study period. Of these, 21 (12%) children received 23 (13.3%) transplants for unresectable MPPHTs: 16 hepatoblastomas (HBs), 3 embryonal cell sarcomas (ECS), and 2 hepatocellular carcinomas (HCCs). There was no significant difference in 1-, 3-, and 10-year patient and graft survival rates between MPPHT and non-MPPHT patients (95.2%, 81.2%, 81.2%, and 95.2%, 72,2%, 72.2% for MPPHT vs 92.7%, 89.8%, 87.6% and 85.4%, 81.1%, 75% for the non-MPPHT group, respectively) (p > 0.05). Rates of 1-, 5-, and 10-year disease-free survival for MPPHT patients were 76%, 76%, and 76%, respectively. Median age at transplantation for MPPHT patients was 3.1 years (range 58 days to 17 years), median listing time was 81 days, and median wait list time was 15 days. Eight (38%) children had 2 tumors or more and 4 of 16 (25%) HB patients had metastatic disease at presentation. All children received neoadjuvant treatment, with radiographic response in 19 of 21 patients. Presence of metastatic HB at presentation, International Society of Pediatric Oncology Epithelial Liver (SIOPEL) high risk status, and persistently elevated alpha fetoprotein levels after neoadjuvant chemotherapy might be risk factors for tumor recurrence and decreased survival.

Conclusions: Liver transplantation is an excellent option for select patients with unresectable MPPHTs, with outcomes comparable to those after transplantation for nonmalignant causes.

PubMed Disclaimer

Comment in

  • Discussion.
    [No authors listed] [No authors listed] J Am Coll Surg. 2017 Jul;225(1):113-114. doi: 10.1016/j.jamcollsurg.2017.04.026. J Am Coll Surg. 2017. PMID: 28648337 No abstract available.

References

REFERENCES

    1. Avila LF, Luis AL, Hernandez F, et al. Liver transplantation for malignant tumors in children. Eur J Pediatr Surg. 2006;16:411-414.
    1. Fernandez-Pineda I, Cabello-Laureano R. Differential diagnosis and management of liver tumors in infants. World J Hepatol. 2014;6:486-495.
    1. Otte JB. Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat Rev. 2010;36:360-371.
    1. Pham TH, Iqbal CM, Grams JM, et al. Outcomes of primary liver cancer in children: an appraisal of experience. J Pediatr Surg. 2007;42:834-839.
    1. Hiyama E. Current therapeutic strategies for childhood hepatic malignant tumors. Int J Clin Oncol. 2013;18:943-945.